Our previous work highlighted the effectiveness of Gal3 inhibition in disrupting Mucin 16 (MUC16) induced tumor-promoting properties and its reduction improved overall survival in breast and ovarian xenograft models [15]. This evidence concerns the gene LGALS3 and neoplasm.